Promising brain tumor drug trial pulled before it started
NCT ID NCT06012929
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study planned to test an oral drug called ONC201 (dordaviprone) in people with a type of brain tumor called meningioma that had come back or was not responding to other treatments. One group would have taken the drug before surgery to see how much reached the tumor, and another group would have taken it to see if it slowed tumor growth. However, the trial was withdrawn before any patients were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ONC201 (dordaviprone), an oral medication taken once per week
What this could lead to
If it had worked, this could point toward a new treatment option for people with meningioma that has come back or is hard to treat.
What could go wrong
This trial was withdrawn before enrolling any participants, so no results are available. The study was very small and early-stage, so even if it had run, success was uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.